ArticleChest2016
Procalcitonin as an Early Marker of the Need for Invasive Respiratory or Vasopressor Support in Adults With Community-Acquired Pneumonia.
Article in Chest, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Baseline Predictors of Adverse Outcome and Survival in Adults Hospitalized with Invasive Pneumococcal Disease.Healthcare (Basel, Switzerland) · 2026Article
- Development and validation of a machine learning model for critical progression risk in pediatric severe community-acquired pneumonia.Scientific reports · 2025Article
- Role of biomarkers in antimicrobial stewardship: physicians' perspectives.The Korean journal of internal medicine · 2024Article
- The independent predictive value of admission serum ferritin concentration for prognosis in elderly patients with community-acquired pneumonia in the emergency department.Frontiers in cellular and infection microbiology · 2024Article
- The Role of Biomarkers in Influenza and COVID-19 Community-Acquired Pneumonia in Adults.Antibiotics (Basel, Switzerland) · 2023Review
- Severe community-acquired pneumonia.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Using Precision Medicine for the Diagnosis and Treatment of Viral Pneumonia.Advances in therapy · 2022Review
- Pneumonia Severity in Children: Utility of Procalcitonin in Risk Stratification.Hospital pediatrics · 2021Article
- Article
- Antibiotic Stewardship in the Intensive Care Unit. An Official American Thoracic Society Workshop Report in Collaboration with the AACN, CHEST, CDC, and SCCM.Annals of the American Thoracic Society · 2020Article
- Antibiotic Treatment Failure and Associated Outcomes Among Adult Patients With Community-Acquired Pneumonia in the Outpatient Setting: A Real-world US Insurance Claims Database Study.Open forum infectious diseases · 2020Article
- Biomarkers in Community-Acquired Pneumonia (Cardiac and Non-Cardiac).Journal of clinical medicine · 2020Review
- Severe flu management: a point of view.Intensive care medicine · 2020Review
- Clinical Progress Note: Procalcitonin in the Management of Pediatric Lower Respiratory Tract Infection.Journal of hospital medicine · 2019Review
- Low Admission Plasma Gelsolin Concentrations Identify Community-acquired Pneumonia Patients at High Risk for Severe Outcomes.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Procalcitonin as a Decision-Supporting Marker of Urgent Biliary Decompression in Acute Cholangitis.Digestive diseases and sciences · 2018Article
- Pneumococcal Community-Acquired Pneumonia Detected by Serotype-Specific Urinary Antigen Detection Assays.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Article
- Article
- Procalcitonin Value Is an Early Prognostic Factor Related to Mortality in Admission to Pediatric Intensive Care Unit.Critical care research and practice · 2018Article
- A clinical approach to the threat of emerging influenza viruses in the Asia-Pacific region.Respirology (Carlton, Vic.) · 2017Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
17 authors.
Funding
Abstract
backgroundPredicting the need for intensive care among adults with community-acquired pneumonia (CAP) remains challenging.
methodsUsing a multicenter prospective cohort study of adults hospitalized with CAP, we evaluated the association of serum procalcitonin (PCT) concentration at hospital presentation with the need for invasive respiratory or vasopressor support (IRVS), or both, within 72 h. Logistic regression was used to model this association, with results reported as the estimated risk of IRVS for a given PCT concentration. We also assessed whether the addition of PCT changed the performance of established pneumonia severity scores, including the pneumonia severity index and the American Thoracic Society minor criteria, for prediction of IRVS.
resultsOf 1,770 enrolled patients, 115 required IRVS (6.5%). Using the logistic regression model, PCT concentration had a strong association with IRVS risk. Undetectable PCT (< 0.05 ng/mL) was associated with a 4% (95% CI, 3.1%-5.1%) risk of IRVS. For concentrations < 10 ng/mL, PCT had an approximate linear association with IRVS risk: for each 1 ng/mL increase in PCT, there was a 1% to 2% absolute increase in the risk of IRVS. With a PCT concentration of 10 ng/mL, the risk of IRVS was 22.4% (95% CI, 16.3%-30.1%) and remained relatively constant for all concentrations > 10 ng/mL. When added to each pneumonia severity score, PCT contributed significant additional risk information for the prediction of IRVS.
conclusionsSerum PCT concentration was strongly associated with the risk of requiring IRVS among adults hospitalized with CAP and is potentially useful for guiding decisions about ICU admission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.